羟基脲治疗感染性结石:5年随访

Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association Pub Date : 1983-01-01

M J Smith

{"title":"羟基脲治疗感染性结石:5年随访","authors":"M J Smith","doi":"","DOIUrl":null,"url":null,"abstract":"Hydroxyurea in a morning dose of 500 mg along with Macrodantin, 100 mg, has been used for more than five years as an adjunct to the management of retained struvite stones. Mild reversible toxicity occurs in 10 per cent. Urine sterility can be achieved in ninety per cent and no growth of the retained stone occurs.","PeriodicalId":76354,"journal":{"name":"Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association","volume":"20 ","pages":"466-8"},"PeriodicalIF":0.0000,"publicationDate":"1983-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Management of infected stone disease with hydroxyurea: a five year follow-up.\",\"authors\":\"M J Smith\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hydroxyurea in a morning dose of 500 mg along with Macrodantin, 100 mg, has been used for more than five years as an adjunct to the management of retained struvite stones. Mild reversible toxicity occurs in 10 per cent. Urine sterility can be achieved in ninety per cent and no growth of the retained stone occurs.\",\"PeriodicalId\":76354,\"journal\":{\"name\":\"Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association\",\"volume\":\"20 \",\"pages\":\"466-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1983-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

羟基脲早晨剂量为500毫克，Macrodantin为100毫克，已被用作治疗鸟粪石结石的辅助药物超过五年。10%的人出现轻度可逆毒性。90%的人可以达到尿不育，并且不会发生残留结石的生长。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Management of infected stone disease with hydroxyurea: a five year follow-up.

Hydroxyurea in a morning dose of 500 mg along with Macrodantin, 100 mg, has been used for more than five years as an adjunct to the management of retained struvite stones. Mild reversible toxicity occurs in 10 per cent. Urine sterility can be achieved in ninety per cent and no growth of the retained stone occurs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association

自引率

0.00%

发文量